Health Canada Approves Zepbound for OSA in Adults With Obesity
Tirzepatide injection becomes the first medication authorized in Canada for moderate to severe OSA, demonstrating significant reductions in breathing disruptions in clinical trials.
Tirzepatide injection becomes the first medication authorized in Canada for moderate to severe OSA, demonstrating significant reductions in breathing disruptions in clinical trials.
The medical technology company is transitioning leadership to focus on its next phase of growth and commercial traction for its obstructive sleep apnea therapy in the US market.
'The medical device industry has long assumed that mass production and true personalization are incompatible. FormFit proves they are not.'
This chart highlights key specifications and features among CPAP pillows, including adjustability, dimensions, materials, washability, and price.
A newly published study reports significant clinical improvement and brain-network modulation in patients treated with the noninvasive neurostimulation device.
Josza brings extensive experience across the medical and dental device industries to his new leadership role, effective May 11.
The new dual-product system aims to support the 24-hour wellness cycle, accompanied by a strategic partnership with the Calm app to offer curated sleep content.
A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.
A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.